REFERENCES
Ahmad M, Zeitlin IJ, Parratt JR, Pitt AR (2006). Degradation of
bradykinin, a cardioprotective substance, during a single passage
through isolated rat-heart. Archives of pharmacal research29: 241-248.
Amaral FA, Bastos LF, Oliveira TH, Dias AC, Oliveira VL, Tavares
LD, et al. (2016). Transmembrane TNF-alpha is sufficient for
articular inflammation and hypernociception in a mouse model of gout.European journal of immunology 46: 204-211.
Bakhle YS (1968). Conversion of angiotensin I to angiotensin II by
cell-free extracts of dog lung. Nature 220: 919-921.
Campbell DJ (2013). Bradykinin Peptides. In: Kastin AJ (ed).Handbook of Biologically Active Peptides , 2nd edn. p^pp
1386-1393.
Cayla C, Labuz D, Machelska H, Bader M, Schafer M, Stein C (2012).
Impaired nociception and peripheral opioid antinociception in mice
lacking both kinin B1 and B2 receptors. Anesthesiology116: 448-457.
Chan WC, White PD (2000). Fmoc Solid Phase Peptide Synthesis - A
Practical Approach . edn. Oxford University Press.
Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M,
et al. (2010). Icatibant, a new bradykinin-receptor antagonist, in
hereditary angioedema. The New England journal of medicine363: 532-541.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz
MA, et al. (2018). Experimental design and analysis and their
reporting II: updated and simplified guidance for authors and peer
reviewers. British journal of pharmacology 175: 987-993.
Elliott DF, Horton EW, Lewis GP (1960). Actions of pure bradykinin.The Journal of physiology 153: 473-480.
Ferreira SH (1965). A Bradykinin-Potentiating Factor (Bpf) Present in
the Venom of Bothrops Jararca. British journal of pharmacology and
chemotherapy 24: 163-169.
Ferreira SH, Vane JR (1967). The disappearance of bradykinin and
eledoisin in the circulation and vascular beds of the cat. British
journal of pharmacology and chemotherapy 30: 417-424.
Ferreira SH, Greene LH, Alabaster VA, Bakhle YS, Vane JR (1970).
Activity of various fractions of bradykinin potentiating factor against
angiotensin I converting enzyme. Nature 225: 379-380.
Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et
al. (2020). A mechanistic model and therapeutic interventions for
COVID-19 involving a RAS-mediated bradykinin storm. eLife 9.
Gomes ER, Lara AA, Almeida PW, Guimaraes D, Resende RR,
Campagnole-Santos MJ, et al. (2010). Angiotensin-(1-7) prevents
cardiomyocyte pathological remodeling through a nitric oxide/guanosine
3’,5’-cyclic monophosphate-dependent pathway. Hypertension55: 153-160.
Guatimosim S, Amaya MJ, Guerra MT, Aguiar CJ, Goes AM, Gomez-Viquez
NL, et al. (2008). Nuclear Ca2+ regulates cardiomyocyte function.Cell calcium 44: 230-242.
Guyenet PG (2006). The sympathetic control of blood pressure.Nature reviews. Neuroscience 7: 335-346.
Habal FM, Movat HZ (1976). Kininogens of human plasma. Seminars in
thrombosis and hemostasis 3: 27-42.
Hasan AA, Amenta S, Schmaier AH (1996). Bradykinin and its metabolite,
Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced
platelet activation. Circulation 94: 517-528.
Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D (2015). Remote
ischemic conditioning. Journal of the American College of
Cardiology 65: 177-195.
Jesus ICG, Scalzo S, Alves F, Marques K, Rocha-Resende C, Bader M,
et al. (2018). Alamandine acts via MrgD to induce AMPK/NO activation
against ANG II hypertrophy in cardiomyocytes. American journal of
physiology. Cell physiology 314: C702-C711.
Kempe S, Fois G, Brunner C, Hoffmann TK, Hahn J, Greve J (2020).
Bradykinin signaling regulates solute permeability and cellular junction
organization in lymphatic endothelial cells. Microcirculation27: e12592.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010).
Improving bioscience research reporting: the ARRIVE guidelines for
reporting animal research. PLoS biology 8: e1000412.
Kopylov AT, Myasoedov NF, Dadayan AK, Zgoda VG, Medvedev AE, Zolotarev
YA (2016). Use of deuterium labeling by high-temperature solid-state
hydrogen-exchange reaction for mass spectrometric analysis of bradykinin
biotransformation. Rapid communications in mass spectrometry :
RCM 30: 1283-1294.
Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL
(2005). International union of pharmacology. XLV. Classification of the
kinin receptor family: from molecular mechanisms to pathophysiological
consequences. Pharmacological reviews 57: 27-77.
Lilley E, Stanford SC, Kendall DE, Alexander SPH, Cirino G, Docherty
JR, et al. (2020). ARRIVE 2.0 and the British Journal of
Pharmacology: Updated guidance for 2020. British journal of
pharmacology 177: 3611-3616.
Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T))
Method. Methods 25: 402-408.
Marceau F, Bachelard H, Bouthillier J, Fortin JP, Morissette G, Bawolak
MT, et al. (2020). Bradykinin receptors: Agonists, antagonists,
expression, signaling, and adaptation to sustained stimulation.International immunopharmacology 82: 106305.
Marshall P, Heudi O, McKeown S, Amour A, Abou-Shakra F (2002). Study of
bradykinin metabolism in human and rat plasma by liquid chromatography
with inductively coupled plasma mass spectrometry and orthogonal
acceleration time-of-flight mass spectrometry. Rapid
communications in mass spectrometry : RCM 16: 220-228.
McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P,
et al. (1991). Expression cloning of a rat B2 bradykinin receptor.Proceedings of the National Academy of Sciences of the United
States of America 88: 7724-7728.
Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck
KA, et al. (1994). Expression cloning of a human B1 bradykinin
receptor. The Journal of biological chemistry 269:21583-21586.
Morinelli TA, Webb JG, Jaffa AA, Privitera PJ, Margolius HS (2001). A
metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against
the deleterious effects of lipopolysaccharide in rats. The Journal
of pharmacology and experimental therapeutics 296: 71-76.
Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ (2000). Metabolism
of bradykinin In vivo in humans: identification of BK1-5 as a stable
plasma peptide metabolite. The Journal of pharmacology and
experimental therapeutics 294: 263-269.
Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, et al.(2004). Bradykinin induces mitochondrial ROS generation via NO, cGMP,
PKG, and mitoKATP channel opening and leads to cardioprotection.American journal of physiology. Heart and circulatory physiology286: H468-476.
Orfanos SE, Langleben D, Khoury J, Schlesinger RD, Dragatakis L, Roussos
C, et al. (1999). Pulmonary capillary endothelium-bound
angiotensin-converting enzyme activity in humans. Circulation99: 1593-1599.
Park WK, St-Pierre SA, Barabe J, Regoli D (1978). Synthesis of peptides
by the solid-phase method. III. Bradykinin: fragments and analogs.Canadian journal of biochemistry 56: 92-100.
Ramirez-Molina C, Heudi O, Pullen M, Marshall PS (2006). Study of
bradykinin metabolism by rat lung tissue membranes and rat kidney brush
border membranes by HPLC with inductively coupled plasma-mass
spectrometry and orthogonal acceleration time-of-flight mass
spectrometry. Journal of peptide science : an official publication
of the European Peptide Society 12: 220-226.
Redman LW, Regoli D, Tustanoff ER (1979). Immunological and biological
activities of fragments and analogs of bradykinin. Canadian
journal of biochemistry 57: 529-539.
Regoli D, Gobeil F, Jr. (2015). Critical insights into the beneficial
and protective actions of the kallikrein-kinin system. Vascular
pharmacology 64: 1-10.
Regoli D, Gobeil F (2016). Kinins and peptide receptors.Biological chemistry 397: 297-304.
Regoli D, Barabe J, Park WK (1977). Receptors for bradykinin in rabbit
aortae. Canadian journal of physiology and pharmacology55: 855-867.
Roch-Arveiller M, Caranikas S, Regoli D, Giroud JP (1983). Effects of
bradykinin and some of its fragments on smooth muscles and chemotaxis.European journal of pharmacology 88: 99-103.
Rocha-Resende C, Leao NM, de Lima ME, Santos RA, Pimenta AMC,
Verano-Braga T (2017). Moving pieces in a cryptomic puzzle: Cryptide
from Tityus serrulatus Ts3 Nav toxin as potential agonist of muscarinic
receptors. Peptides 98: 70-77.
Rocha-Resende C, Roy A, Resende R, Ladeira MS, Lara A, de Morais Gomes
ER, et al. (2012). Non-neuronal cholinergic machinery present in
cardiomyocytes offsets hypertrophic signals. J Mol Cell Cardiol53: 206-216.
Rocha ESM, Beraldo WT, Rosenfeld G (1949). Bradykinin, a hypotensive and
smooth muscle stimulating factor released from plasma globulin by snake
venoms and by trypsin. The American journal of physiology156: 261-273.
Ryan JW, Roblero J, Stewart JM (1968). Inactivation of bradykinin in the
pulmonary circulation. The Biochemical journal 110:795-797.
Ryan JW, Berryer P, Chung AY, Sheffy DH (1994). Characterization of rat
pulmonary vascular aminopeptidase P in vivo: role in the inactivation of
bradykinin. The Journal of pharmacology and experimental
therapeutics 269: 941-947.
Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M
(2019). The renin-angiotensin system: going beyond the classical
paradigms. American journal of physiology. Heart and circulatory
physiology 316: H958-H970.
Schneider CA, Rasband WS, Eliceiri KW (2012). NIH Image to ImageJ: 25
years of image analysis. Nature methods 9: 671-675.
Schoemaker RG, van Heijningen CL (2000). Bradykinin mediates cardiac
preconditioning at a distance. American journal of physiology.
Heart and circulatory physiology 278: H1571-1576.
Semis M, Gugiu GB, Bernstein EA, Bernstein KE, Kalkum M (2019). The
Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse
Plasma. Analytical chemistry 91: 6440-6453.
Suzuki K, Abiko T, Endo N (1969). Synthesis of every kinds of peptide
fragments of bradykinin. Chemical & pharmaceutical bulletin17: 1671-1678.
Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et
al. (2017). A pathology atlas of the human cancer transcriptome.Science 357.
van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q,
Bruggemann RJ, et al. (2020). Kallikrein-kinin blockade in
patients with COVID-19 to prevent acute respiratory distress syndrome.eLife 9.
Verano-Braga T, Martins ALV, Motta-Santos D, Campagnole-Santos MJ,
Santos RAS (2020). ACE2 in the renin-angiotensin system. Clinical
science 134: 3063-3078.
Wick MJ, Harral JW, Loomis ZL, Dempsey EC (2018). An Optimized Evans
Blue Protocol to Assess Vascular Leak in the Mouse. Journal of
visualized experiments : JoVE .
Yang HY, Erdos EG, Levin Y (1970). A dipeptidyl carboxypeptidase that
converts angiotensin I and inactivates bradykinin. Biochimica et
biophysica acta 214: 374-376.